High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6122-6129

  Henrique, Rui ^a   Ribeiro, Franclim R ^a   Fonseca, Daniel ^a   Hoque, Mohammad O ^c   Carvalho, André L ^c   Costa, Vera L ^a   Pinto, Mafalda ^a   Oliveira, Jorge ^a   Teixeira, Manuel R ^a   Sidransky, David ^c   Jerónimo, Carmen ^a,b,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; APC GENE; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CCND2 GENE; CLINICAL EVALUATION; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EPIGENETICS; FOLLOW UP; GENE; GLEASON SCORE; GSTP1 GENE; HUMAN; HUMAN TISSUE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METHYLATION; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT CARE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RARB2 GENE; RASSF1A GENE; SEROLOGY; UNIVARIATE ANALYSIS;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; AGED, 80 AND OVER; BIOPSY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 35948929442     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1042     Document Type: Article

References (23)

1. Jemal A, Siegel R,Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
3. King CR, Long JP. Prostate biopsy grading errors: a sampling problem? Int J Cancer 2000;90:326-30.
4. Allsbrook WC, Jr., Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001;32:81-8.
5. Jerónimo C, Henrique R, Sidransky D. Uses of DNA methylation in cancer diagnosis and risk assessment. In: Esteller M, editor. DNA methylation. Approaches, methods and applications. CRC Press: Boca Raton; 2004. p.11-26.
6. Costa VL, Henrique R, Jerónimo C. Epigenetic markers for molecular detection of prostate cancer. Dis Markers 2007;23:31-41.
7. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037-43.
8. Rosenbaum E, Hoque MO, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005;11:8321-5.
9. Ribeiro FR, Jerónimo C , Henrique R, et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 2006;12:3961-70.
10. Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7:2727-30.
11. Gleason DF, Mellinger GT. Predictionof prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
12. Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C. Prostate. In: Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C, editors. Illustrated guide to the TNM/pTNM classification of malignant tumors. Springer-Verlag: Heidelberg; 1997. p. 278-80.
13. Jerónimo C, Henrique R, Hoque MO, et al. Quantitative RARβ2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 2004;10:4010-4.
14. Jerónimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 hypermethylation distinguishes between non-neoplastic prostatic tissue and organ confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93:1747-52.
15. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371-5.
16. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-12.
17. Henrique R, Costa VL, Cerveira N, et al. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med 2006;84:911-8.
18. Jerónimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004;10:8472-8.
19. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.
20. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86.
21. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004;10:5518-22.
22. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005;11:4097-106.
23. Ribeiro FR, Henrique R, Martins AT, Jerónimo C, Teixeira MR. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol 2007;52:116-25.